Tezepelumab is associated with beneficial changes in nasal polyp gene expression in patients with chronic rhinosinusitis with ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal ...

Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Please provide your email address to receive an email when new articles are posted on . Three currently available type 2 biologics approved for asthma appeared effective in treating chronic ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study ...

Nasal polyps - soft, grape-like outgrowths that can appear in the nasal passages and sinuses - can be chronic and relentless. Although noncancerous, these outgrowths can grow large enough to block the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prevalence of type 2 inflammation ranged from 64.2% to ...

Nasal polyps are noncancerous growths that can form when your nasal passages and sinuses get inflamed. Small polyps may not cause any symptoms, but they can cause issues as they grow and multiply ...

The first head-to-head randomized clinical trial to compare biologics in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma showed an advantage to dupilumab (Dupixent) over ...